WP2: Psychiatry
Neurodevelopmental, mood, anxiety and addictive disorders are highly prevalent, affecting up to 25-30% of the general population and contributing to an impaired quality of life. They are characterized by strong symptom overlap, high severity, functional disability, and recurrence or chronicity. Currently available treatments are effective for some individuals but not for others. This may be due to the diversity and complexity of the clinical profiles and biological substrates, making the determination of relevant predictors of therapeutic responses and new treatments a major issue. Therefore, based on our previous animal and human research, the main objectives of WP2 will be to better identify the clinical, behavioral and neurobiological characteristics of these disorders, define key predictive factors for outcome and develop innovative treatments.
Prof. Bruno Aouizerate is psychiatrist and head of the regional reference center for the management and treatment of anxiety and depressive disorders. He is member of the national network known as...
Dr. Cyril Herry is a neuroscientist and is a team leader at the INSERM Neurocenter Magendie (Neuronal circuits of associative learning). He has wide experience in behavioral neurophysiology and is...